Month: January 2024
Meet with Christopher Kata, Director of Sales & Marketing February 11th – 14th, 2024 at the SCOPE Summit for Clinical Operations Executives in Orlando, Florida. Christopher and the TrialStat team are exhibiting in booth # 1020. Christopher Kata, Director of Sales & Marketing905 [email protected] Event: SCOPE – Summit for Clinical Operations Executives When: February 11th…
Read More
Excerpt from the Press Release: LA JOLLA, Calif.–(BUSINESS WIRE)–Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced positive topline data from the PACIFIC Study evaluating bexicaserin (LP352), a potentially best-in-class and highly selective, oral, novel 5-HT2C receptor superagonist for seizures associated with a broad…
Read More
– In Phase 1/2 ACHIEVE Trial, DYNE-101 Demonstrated Dose-Dependent Splicing Correction, Muscle Delivery and DMPK Knockdown – – All Evaluable Patients in the 3.4 mg/kg Cohort Treated with DYNE-101 Q4W Demonstrated Consistent Splicing Correction with a 19% Mean Improvement Across 22-Gene Panel at 3 Months – – Improvement in Myotonia (vHOT) as well as Fatigue…
Read More
Kara N. Fitzgerald1 , Tish Campbell2 , Suzanne Makarem2 , Romilly Hodges3 Excerpt from the Press Release: Abstract Here we report on a case series of six women who completed a methylation-supportive diet and lifestyle program designed to impact DNA methylation and measures of biological aging. The intervention consisted of an 8-week program that included…
Read More
Clinical Success Achieved in Second Cohort of Patients Excerpt from the Press Release: PRINCETON, N.J., Jan. 4, 2024 /PRNewswire/ — Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today preliminary top-line results of its…
Read More
“Equity and representation in science matter more than ever, and the Rosalind Franklin Society continues its mission to recognize, foster, and advance the critical contributions of women and underrepresented minorities in science. Our annual year-end conference highlights the innovators and changemakers with unique experiences and leadership.” To learn more about this incredible event and to register for…
Read More
Excerpt from the Press Release: SAN FRANCISCO AND BOSTON, Jan. 3, 2024 /PRNewswire/ — MapLight Therapeutics, a clinical-stage biopharmaceutical company working to develop targeted novel therapeutics to improve the lives of people with brain disorders, today announced completion of a Phase 1 clinical trial evaluating the bioavailability, safety, and tolerability of an extended release formulation…
Read More
Phase 1 study aims to evaluate safety and tolerability of a single ascending dose of RCT1100 in patients with PCD caused by mutations in the DNAI1 gene RCT1100 is the first clinical evaluation of an inhaled mRNA-based therapy designed to restore ciliary function in people with PCD Excerpt from the Press Release: MENLO PARK, Calif.–(BUSINESS…
Read More- « Previous
- 1
- 2